Lupin has acquired US rights for Antara (Fenofibrate capsules 43mg, and 130mg) for $38.61m from Oscient Pharmaceuticals.
Lupin had filed an ANDA for fenofibrate capsules 43mg and 130mg. The company sold the ANDA to Dr Reddy’s Laboratories and also settled the pending litigation relating to the product.
Vinita Gupta, group president and CEO of Lupin, said: “We are very excited with our second NDA acquisition within a span of four months. The Antara acquisition demonstrates Lupin’s success in, and commitment to building its brand franchise and equity in the US. It underlines Lupin’s differentiated strategy for the US market. Antara is a step forward that will help us strengthen and grow our brand business. Since Antara is a previously approved, commercial product, our sales and marketing efforts will commence immediately and we are optimistic of it contributing positively to our topline and bottomline in the coming quarters and years.”
Antara is aimed at adjunct treatment of hypercholesterolemia and hyper-triglyceridemia in combination with diet. Reportedly, the Antara acquisition enables Lupin to enter the primary care market with a three products portfolio.